

Q3 2024 *Results*



- Our strong performance continues in Q3, boosted by sales of flu and RSV vaccines, the steady progress of our new pharma launches, and the continued momentum of our best-in-class biologic, now approved in six type 2 inflammatory diseases and treating more than 1 million patients worldwide. •

Paul Hudson

Chief Executive Officer, Sanofi

Q3 2024 company sales

€13,438m

+15.7% at constant exchange rates
+12.3% on a reported basis

Q3 2024 business earnings per share

€2.86

+17.6% at constant exchange rates
+12.2% on a reported basis

Continued robust sales growth



Dupixent

€3,476m

+23.8%
at constant
exchange rates



Pharma launches

€727m

+67.1%
at constant
exchange rates



Vaccines

€3,802m

+25.5%
at constant
exchange rates



Other medicines

€4,162m

+0.4%
at constant
exchange rates



Opella

€1,271m

+7.9%
at constant
exchange rates

sanofi

Q3 2024 *Results*

Sales by geography

US
€6,886m

Europe
€2,886m

Rest of the World
€3,666m

Pipeline progress



4 regulatory approvals

4 positive phase 3 data readouts

*Opella separation**



- Sanofi and CD&R enter exclusive negotiations to **transfer a 50% controlling stake** in Opella
- Sanofi to remain **a significant shareholder**

**The proposed transaction is subject to finalization of definitive agreements, completion of the appropriate social processes and subject to customary closing conditions.*

For further information on Q3 2024 results and definitions of financial indicators, please refer to the press release issued on October 25, 2024 at: www.sanofi.com/en/investors